COVID-19相关肺纤维化的病因机制及治疗的研究进展

Research progress on the mechanism,and treatment of COVID⁃19 related pulmonary fibrosis

新型冠状病毒肺炎(COVID-19)是一种由SARS-CoV-2感染所引起的急性呼吸道传染性疾病。随着近期COVID-19疫情的常态化流行,COVID-19患者的影像学及病理学研究表明,部分患者SARS-CoV-2感染后可出现肺纤维化改变,COVID-19相关肺纤维化正成为影响患者预后生存质量的重要影响因素,严重威胁患者的生命健康。目前,COVID-19相关肺纤维化的发病机制尚未明确,治疗方案多基于既往肺纤维化疾病的诊治经验,本文通过总结SARS-CoV-2感染后肺损伤及纤维化的发生机制和相关治疗方案,为临床的防治及干预提供一定参考。

COVID⁃19 is an acute respiratory infectious disease caused by SARS⁃CoV⁃2 infection.With the recent normaliza⁃tion of the COVID⁃19 epidemic,imaging and pathological studies of COVID⁃19 patients have shown that some patients can devel⁃op pulmonary fibrotic changes after SARS⁃CoV⁃2 infection,and COVID⁃19⁃associated pulmonary fibrosis is becoming an impor⁃tant influencing factor affecting the quality of patients´prognostic survival,which is a serious threat to the life and health of pa⁃tients.At present,the pathogenesis of COVID⁃19⁃associated pulmonary fibrosis has not been clarified,and the treatment plan is mostly based on the previous experience in the diagnosis and treatment.In this paper,we summarize the mechanism of lung injury and fibrosis after SARS⁃CoV⁃2 infection and the related treatment plan,to provide a certain reference for the prevention,treat⁃ment and intervention of the clinic.